Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone...
74 insider purchases on record · latest filing 2026-02-20.
Insiders have also filed 85 sale transactions at OCUL.